Clinical Trial Update: Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease [Phase 3]

View source ↗

Summary

Phase 3 trial assessing efficacy and safety of tolvaptan in adults with autosomal dominant polycystic kidney disease (late stage 2 to early stage 4 CKD). Result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Polycystic Kidney Disease
• Chronic Kidney Disease

Drugs mentioned

• tolvaptan (tolvaptan)

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Chronic Kidney Disease, Autosomal Dominant Polycystic Kidney Disease | Phase 3 | Status: COMPLETED | Results posted: 2018-08-08